Document is current

Any future updates will be listed below

895 Enhanced anti-tumor efficacy by combination of checkpoint immunotherapy and antibody-drug conjugates utilizing the topoisomerase I inhibitor linker-payload AZ’0133

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0895

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark